Patient Bedrooms

Regular Off Off

Three-quarters of the 800 beds in the Brunel building are single rooms. The most striking feature of the single rooms is how spacious they are; each single room is 16.6sqm in floor area with the en-suite toilet and shower being 5.3sqm.

Their size means that we’ve been able to incorporate features that make nursing more efficient and this means better care for our patients. Put simply, the ample space means we’ve been able to make it easier to work.

Each 32-bed ward has 24 single rooms and two four-bed bays. We know that single rooms provide considerable benefits for patients, including control of infection, reducing risk of clinical errors (there are fewer distractions) and allowing privacy.

Each room has a wall-mounted medication cabinet, overhead tracking for a hoist, over-bed table, bedside basin, bedside cabinet and a TV. The size of the rooms allow for an electric profiling bed and reclining chair, which can also be used by visitors. A ‘smart-wall panel’ to the side of the bed-head incorporates oxygen, medical air, suction and, in some rooms, monitors. Throughout the room there are multiple power points.

Doorways are angled so that four single rooms can be observed at once and each room has an observation window.

Between each pair of rooms there is a standing perch at which staff can write up notes or enter information electronically while maintaining good observation of patients.
The main nursing stations have a drug preparation area and each has a system of tubes enabling the immediate delivery of drugs to key points. An electric call panel flashes to show the room the patient is calling from.

The 4 bed bays are single sex, spacious and have their own bathroom.

Did you know?

25% of the bedrooms will face onto the Atrium, including all of the four bed bays.

The Atrium

Regular Off Off

Upon entering the building, one of the most striking elements of the Brunel building is its 280 metre long atrium connecting one end of the building to the other.

This large open space has large areas of glass walls, with different colours marking the different areas, and a fully glazed concourse roof bringing light into this space.
From here you check in using the self-check-in screens available and then take the lifts or stairs to the area required. There is a welcome desk with staff able to help with any questions about check-in.

At the front entrance of the Brunel building, the height of the atrium is the same as the nave of Westminster Abbey and at the other end, where the Emergency Department (ED) is located, as high as Bristol Cathedral’s nave.

Did you know?

1,750,000 m of data cabling and 5,500,000 m of electrical cable was used in the Brunel building.

Designing the Brunel building

Regular Off Off

Our brief to bidders was less conventional than for other new hospital developments as we wanted this hospital to stand out from the crowd not only for its excellent clinical services but also for its high quality building and site design. Good internal and external design was as important to us as getting the clinical functionality right.

Our strong belief, based on research, is that good design reaps its own rewards in terms of wellbeing and recuperation rates for patients and boosts moral and job satisfaction for staff.

We set out six themes in our strategic design vision which were:

  • Innovation and patient care – providing cutting edge design geared for top performance
  • Flexibility – design in at the outset the ability for the hospital to respond to changes in the way healthcare is provided
  • Welcoming Landscape – apply urban design principles to the development of the whole site, rather than only focusing on the building
  • Connecting the inside to the outside – bring views from outside in, get light into the building through glazing and layout and get long views out
  • Excellent finishes – high quality, non-institutional building and internal finishes
  • Sustainable development – low carbon footprint, sustainable construction practice, waste minimisation.

 

 

Did you know?

1,750,000 m of data cabling and 5,500,000 m of electrical cable was used in the Brunel building.

General Fertility, Reproductive Endocrinology and Surgery

Regular Off On A-Z of Services Fertility Clinic

General Fertility, Reproductive Endocrinology and Surgery 

Southmead Hospital provides a fully funded NHS fertility service now known as Southmead General Fertility Clinic. 

Southmead General Fertility Clinic offers couples with fertility problems a full assessment of factors that may be affecting chances of conceiving. The clinic arranges further tests, provides advice and treatment, and when appropriate referral for assisted conception treatment.

The clinic provides the assessment and treatment for couples below (apart from assisted conception services) as detailed below.

Male and female assessment

  • Full range of diagnostic tests.
  • Hormone, androgen profiles.
  • Ovarian reserve assessment (for example AMH).
  • Genetic and chromosome testing.
  • Fertility ultrasound scans.
  • Tubal testing: hysterosalpingography (HSG), laparoscopy and dye test.
  • Repeat semen analysis if required.

Treatments

  • Fertility monitoring for clomifene.
  • Ovulation induction with FSH and monitoring for anovulation.
  • Repair of fallopian tubes.
  • Fertility surgery for fibroids and endometriosis.
  • Hysteroscopic surgery for Asherman’s or uterine abnormalities.
  • Assisted conception treatment advice: expert advice on appropriate treatment options such as IVF/ ICSI/ IUI/ donor sperm.
  • Pre-implantation genetic screening.
  • Arrange referral for the appropriate assisted conception treatment.

The Southmead General Fertility Clinic complements the excellent range of Reproductive Medicine services provided by the Gynaecology Department at North Bristol NHS Trust including:

  • Reproductive Endocrine Clinic (PCOS, amenorrhoea, premature ovarian failure, hirsutism)
  • Recurrent Miscarriage Clinic (patients who have experienced 3 or more miscarriages)

Please look at your local ICS referral guidelines for Fertility.

© North Bristol NHS Trust. This edition published January 2025. Review due January 2028. NBT003774

Support your local hospital charity

Southmead Hospital Charity logo

See the impact we make across our hospitals and how you can be a part of it. 

It's okay to ask

Illustration of 3 clinicians wearing blue scrubs with stethoscopes around necks

Find out about shared decision making at NBT. 

General Fertility Clinic

Breast Care Current Research

Regular Off Off

The Breast Care Centre at NBT provides people at risk of developing breast cancer,  excellent patient centered care and the opportunity to participate in research.

The centre has had a successful research team in place for a number of years delivering complex interventional studies. Please speak to the person treating you to find out if there is a research study that may be able to help you.

Current Studies:

PROSPECTS

The accuracy of two view digital x-ray mammography (2DDM) in breast cancer screening is limited because of superimposition of normal breast structures onto a two dimensional image. Mammography signs of breast cancer may be obscured, particularly in women with dense glandular breast tissue, resulting in delay in diagnosis of cancer. Interval cancer data shows that up to 4000 women per annum (2.88 per 1000 screened) are diagnosed with breast cancer in the interval between screens. Conversely, superimposition of normal tissues may produce features on mammography which are suspicious for cancer and lead to unnecessary recall for further diagnostic tests.

Digital Breast Tomosynthesis (DBT) is an x-ray mammography technique which involves acquiring multiple low dose projection images over a limited angular range (less than 50 degrees). These projection images are reconstructed into a set of images consisting of parallel planes, typically 1mm apart throughout the breast, and provide three dimensional information to the film reader. A synthetic 2D mammogram (S 2D) has been developed using the data from the reconstructed DBT images.

Studies of DBT + 2DDM in screening have shown increased invasive cancer detection rates and lower false positive recall rates.There may be increased costs related to the technology and reading times.

The aim of this trial is to measure the impact and cost-effectiveness of DBT + 2DDM or S 2D in routine screening compared to standard 2DDM.

100,000 women will be recruited using NHS screening sites with DBT mammography equipment. At each site, through a clinic randomisation process, half the trial participants will undergo standard 2DDM (the control group) and half will undergo 2DDM + DBT (the intervention group). All cases will be double read - in the intervention group, one read will be DBT + 2DDM, and one read will be DBT + S 2D. Arbitration or consensus will be used for reader 1/2 discordance.

Project Details
Principal Investigator: Dr Alexandra Valencia
Planned End Date: 31/03/2025
Local Ref: 4441

SMALL TRIAL (v1.0)

Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer – a phase III randomised multi-centre trial

The SMALL study is a research study which will help experts learn whether some women with small breast cancers, which are at low risk of spreading can be safely treated by removal of the cancer using a biopsy needle (under a local anaesthetic) instead of an operation.

The SMALL study will compare open surgery with a minimally invasive technique called vacuum-assisted excision (VAE) for the treatment of small breast cancers found at breast screening. Such small breast cancers have usually been treated with open surgery. The 2012 UK Breast Screening Review showed that breast screening does save lives, but that many women may be having more treatment than is necessary for their breast cancer.  Also, experts do not currently know how open surgery compares with other safe and effective methods to remove small breast cancers. We want to find out what the best treatment is for women like you, so that in future we can only operate on those women who really require surgery. We aim to do this by comparing open surgery with VAE. VAE is widely used in the Breast Screening Programme and has been successfully used instead of an operation to removal small benign tumours in the breast. Based on this, in the SMALL study we would like to find out if VAE (which involves the use of a biopsy needle to remove the cancer) will be as effective as an open operation.

A benefit from taking part in this study is that you will provide information that will help doctors change and improve the way breast cancer is treated in the future. Some women may be able to avoid unnecessary breast surgery in the future as a direct result of the knowledge gained from you taking part in this study.

Project Details
Principal Investigator: Miss Shelley Potter
Planned End Date: 30/06/2025
Local Ref: 4432

ATNEC

Breast cancer sometimes spreads to other areas of the body via the lymphatic system. The first place that cancer cells travel to is the armpit (also known as the axilla). Chemotherapy can be given as a first treatment to target these cells and reduce cancer in the armpit before surgery. This is called neoadjuvant chemotherapy.

After chemotherapy, further treatment to the armpit (either surgery or radiotherapy) is usually offered to everyone. This extra armpit treatment can cause troublesome side effects such as lymphoedema (arm swelling) and shoulder problems.

Sometimes neoadjuvant chemotherapy works so well that it removes all cancer cells in the armpit.

The ATNEC study is looking at whether, in these cases, further armpit treatment is needed.

Project Details
Principal Investigator: Miss Shelley Potter
Planned End Date: 20/12/2025
Local Ref: 4867

EndoNET

This randomised controlled trial; patients are allocated by chance to one of two arms, which determines their treatment schedule. Hormone therapy is usually started after surgery. However, all participants in both trial arms will start hormone treatment (letrozole, anastrozole or exemestane) on joining the trial and prior to surgery. Therefore, they may have the opportunity to start treatment with hormone therapy before they normally would.

Participants in both arms have hormonal treatment for the same total length of time within the trial, but it is the timing of the surgery that differs. The type of surgery all participants will have will be determined by them and their clinical team as part of standard clinical care. Arm 1 will have surgery within 2-4 weeks (up to 8 weeks permitted for trial purposes) of joining the trial; arm 2 will receive surgery after 6 months (+/-1 month) of NET. Participants in arm 2 will receive an ultrasound (USS) scan at 3 months and 5 months to closely monitor their response to this hormone therapy prior to their surgery.

The overall aim is to evaluate whether 6 (+/-1) months of NET reduces surgical burden resulting in better HRQoL over 15 months and higher rates of breast conservation surgery (BCS) for post-menopausal women with ≥15mm (T1-3), strongly ER+, HER2- invasive breast cancer who do not require chemotherapy.

Project Details

Principal Investigator: Miss Shelley Potter

Planned End Date:28/02/2027

Local Ref (R&D no):5176

SWEET

Many women are prescribed hormone therapy following diagnosis and hospital treatment for breast cancer. Hormone therapy significantly reduces the chances of breast cancer returning. Usually, women are recommended to take hormone therapy, in the form of a daily tablet, for several years. However, we know that some women either do not take this medication everyday as prescribed or sometimes stop taking it all together (known as “poor adherence”); this can increase their risk of breast cancer returning. 

SWEET have developed a support package (called HT&Me) which aims to encourage and support women to take their hormone therapy as prescribed, and hopefully reduce the risk of breast cancer returning.

The purpose of the study is to investigate whether the HT&Me support package can improve hormone therapy adherence, and quality-of-life when compared to the standard NHS follow-up care offered in your hospital right now.

Project Details

Principal Investigator: Miss Shelley Potter

Planned End Date: 31/12/2025

Local Red (R&D no): 5500

SIMBAR

The overall purpose of the research is to find out if using a technique called Laser Speckle Imaging (LSI) during surgery for breast reconstruction, can help with surgical decision making. We hope that this will result in significantly fewer complications, and any that do occur after surgery will be much less severe.

This research study is a feasibility study and will include a limited number of women, so we can evaluate the design of the study and whether it is acceptable to women. This will help to design a full-scale clinical trial in the future, and to discover whether this proven technique called LSI is useful in this particular operation. If fewer women are affected by complications and do not need further surgery, the benefit to patients is better quality of life. The benefits to the NHS and society will be cost savings on surgery, drugs, and the other costs associated with complications.

Project Details

Principal Investigator: Miss Philippa Jackson

Planned End Date: 01/04/2025

Local Red (R&D no): 5645

Take Part in Research

Patient & Doctor viewing an x-ray

Become one of the thousands of people taking part in research every day within the NHS.

About Research & Development

NBT Researcher

Find out more about our research and how we're working to improve patient care.

Contact Research

Research & Development
North Bristol NHS Trust
Level 3, Learning & Research building
Southmead Hospital
Westbury-on-Trym
Bristol, BS10 5NB

Telephone: 0117 4149330
Email: research@nbt.nhs.uk

Breast Cancer Research
R&I Breast Care.jpg

Mortuaries

Regular Off Off

The department manages the mortuary facility located in the Brunel Building at Southmead Hospital and the Paediatric/Perinatal mortuary in St Michael’s Hospital.  Since April 2009, when the Bristol City Council/Coroner’s mortuary opened at Flax Bourton the adult service in Southmead Hospital is limited to storage and management of the deceased and the facilitation of viewings.  Requests for autopsies on adult and neonatal deaths may be made through the appropriate mortuary (Southmead 0117  4141700, St Michael's 0117 3425428).  Tissues from autopsies requiring histological examination are sent to the Cellular Pathology Department at NBT for processing.

Cellular Pathology Results & Enquiries

Cytology

Laboratory Opening Hours:
Monday - Friday, 9am - 5pm
Tel: 0117 4149889

Histology

Tel: 0117 414 9890

Test Information

Sample vials for testing

Includes details of sample types, volumes, special precautions, turnaround times & reference ranges.

Mortuaries

What is Cellular Pathology?

Regular Off Off

Cellular pathology is the study of disease in organs, tissues and cells. Histopathology and cytopathology are key diagnostic tests in the initial detection and diagnosis of cancer and other diseases supported by modern molecular techniques. Consultant cellular pathologists are able to provide information on prognosis and help to appropriately direct therapies in post diagnostic treatment.

The cervical cytology screening program detects latent disease in well women and plays an important part in cancer prevention.

If you have any questions about the tests, please visit Lab Tests Online-UK, a patient-centred website written by practicing laboratory doctors and scientists to help members of the public understand the many clinical laboratory tests that are used in the diagnosis, monitoring and treatment of disease.

Cellular Pathology Results & Enquiries

Cytology

Laboratory Opening Hours:
Monday - Friday, 9am - 5pm
Tel: 0117 4149889

Histology

Tel: 0117 414 9890

Test Information

Sample vials for testing

Includes details of sample types, volumes, special precautions, turnaround times & reference ranges.

What is Cellular Pathology?

Meeting Posters (ASM)

Regular Off Off

ASM MICROBE, Boston, 16-20th June, 2016

Reference No.

Document title

Authors

P510

The Antibacterial Effects (ABE) of Two Dosing Regimens of Ceftolozane (TOL) in
Combination with Tazobactam (TAZ) in comparison with meropenem (MER) against Pseudomonas
aeruginosa (PA)

 

KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, AP MacGowan,

 

ASM MICROBE, New Orleans, 1-5th June, 2017

Reference No.

Document title

Authors

P203

The pharmacodynamics of plazomicin and amikacin studied in an in vitro pharmacokinetic model

 

Karen E Bowker1, Alan R Noel1, Marie A Attwood1, Sharon G Tomaselli1, Alasdair P MacGowan1, Kevin Krause2, Eileen Kim2

 

Bcare (ARL) Contact Details

Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB

Telephone: 0117 4146269 or 0117 4146220

Fax: 0117 4146282

Email: arlenquiries@nbt.nhs.uk

Dr Dominic Taylor - Renal

Regular Off On A-Z of Consultants

GMC Number: 6128479

Year of first qualification: 2005, University of Leeds

Specialty: Nephrology (Renal/Kidney Medicine) 

Clinical interests: Kidney disease, Kidney transplantation, Dialysis.

Secretary: Sue Jones / Lynn Tottle

Telephone: 0117 414 7702 / 0117  414 7696

Dr Dominic Taylor has been a consultant nephrologist at North Bristol NHS Trust since 2018. He is departmental lead for quality improvement. He also delivers outreach clinical care at the Royal United Hospital, Bath.

His research interests include the effects of low health literacy on access to kidney transplantation, the effect of pregnancy on the kidneys, and the treatment of heart problems in people with kidney disease.

He is a member of the UK Renal Association and the Royal College of Physicians.

Related Links (to Renal & Renal for Clincians) Taylor